Johnson & Johnson shares two-year Phase 3 data for ICOTYDE in plaque psoriasis

Johnson & Johnson said on October 9, 2026, that it has new two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE (icotrokinra), an oral peptide that blocks the IL-23 receptor, in adults and adolescents aged 12 years and older with moderate-to-severe plaque psoriasis. The data were presented at Fall Clinical Dermatology 2026.

At Week 112, at least 72% of ICOTYDE-treated patients achieved a PASI 90 score, and at least 70% achieved clear or almost clear skin (IGA 0/1) from Week 64 through Week 112. At least 44% achieved PASI 100 and at least 46% achieved clear skin (IGA 0).

Clinically meaningful improvement in itch was sustained in 78% of patients from Week 64 to Week 112. Among PASI 90 responders withdrawn from ICOTYDE at Week 24, 85% regained PASI 90 response within 24 weeks of retreatment.

Johnson & Johnson said safety findings through Week 112 remained consistent with the established safety profile of ICOTYDE, with no new safety signals identified.

ICOTYDE is approved in the U.S. for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. It is also approved in Europe, Japan and China for adults and adolescents with psoriasis.